ArticlePloS one2021
Risk factors for neuropsychiatric symptoms in patients with Parkinson's disease during COVID-19 pandemic in Japan.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- COVID-19 and Parkinson's disease: a systematic review and meta-analysis.Acta neurologica Belgica · 2023Pooled it
- Pooled it
- Dementia and Mental Health During the COVID-19 Pandemic: A Systematic Review.Frontiers in psychiatry · 2022Pooled it
- Changes in non-motor symptoms in patients with Parkinson's disease following COVID-19 pandemic restrictions: A systematic review.Frontiers in psychology · 2022Pooled it
- Factors Associated with Depression and Anxiety in Adults ≥60 Years Old during the COVID-19 Pandemic: A Systematic Review.International journal of environmental research and public health · 2021Pooled it
- From Night to Light: A Bibliometric Analysis of the Global Research Trajectory of Sleep Disorders in Parkinson's Disease.Journal of multidisciplinary healthcare · 2025Article
- Searching Reproducible Brain Features using NeuroMark: Templates for Different Age Populations and Imaging Modalities.NeuroImage · 2024Article
- Remote Assessment of Parkinson's Disease Patients Amidst the COVID-19 Lockdown in Mexico.Brain sciences · 2023Article
- Vulnerability of Parkinson's Patients to COVID-19 and Its Consequences and Effects on Them: A Systematic Review.Parkinson's disease · 2023Review
- Survey on the Impact of the COVID-19 Pandemic on Patients with Parkinson's Disease and Their Caregivers in Japan.Patient preference and adherence · 2023Article
- Living with a Pandemic from Psycho-Social Perspectives: A Narrative Review.Iranian journal of public health · 2022Review
- SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Article
- Moving Forward from the COVID-19 Pandemic: Needed Changes in Movement Disorders Care and Research.Current neurology and neuroscience reports · 2022Review
- Article
- Spotlight on non-motor symptoms and Covid-19.International review of neurobiology · 2022Article
- Social isolation, loneliness and mental health sequelae of the Covid-19 pandemic in Parkinson's disease.International review of neurobiology · 2022Article
- Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?Brain sciences · 2021Review
- Mental health in people with Parkinson's disease during the COVID-19 pandemic: potential for targeted interventions?NPJ Parkinson's disease · 2021Article
- Social and psychological impact of the COVID-19 pandemic on people with Parkinson's disease: a scoping review.Public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The worsening of neuropsychiatric symptoms such as depression, anxiety, and insomnia in patients with Parkinson's disease (PD) has been a concern during the COVID-19 pandemic, because most people worked in self-isolation for fear of infection. We aimed to clarify the impact of social restrictions imposed due to the COVID-19 pandemic on neuropsychiatric symptoms in PD patients and to identify risk factors associated with these symptoms. A cross-sectional, hospital-based survey was conducted from April 22, 2020 to May 15, 2020. PD patients and their family members were asked to complete paper-based questionnaires about neuropsychiatric symptoms by mail. PD patients were evaluated for motor symptoms using MDS-UPDRS part 2 by telephone interview. A total of 71 responders (39 PD patients and 32 controls) completed the study. Although there was no difference in the age distribution, the rate of females was significantly lower in PD patients (35%) than controls (84%) (P < 0.001). Participants with clinical depression (PHQ-9 score ≥ 10) were more common in PD patients (39%) than controls (6%) (P = 0.002). Multivariate logistic regression analysis revealed that an MDS-UPDRS part 2 score was correlated with the presence of clinical depression (PHQ-9 score ≥ 10) and clinical anxiety (GAD-7 score ≥ 7) (clinical depression: OR, 1.31; 95% CI, 1.04-1.66; P = 0.025; clinical anxiety: OR, 1.36; 95% CI, 1.07-1.72; P = 0.013). In the presence of social restrictions, more attention needs to be paid to the neuropsychiatric complications of PD patients, especially those with more severe motor symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.